MET and neoplasm: Lack of MET amplification, Met and phosphorylated Met levels, and insensitivity to the Met inhibitor crizotinib in pre and post-dacomitinib GSCs support the notion that Met does not play a significant role in the emergent tumour resistance in the current case.